Key Clinical Publications

Insmed actively publishes and presents clinical data for ARIKAYCE.

Learn More

Management

Insmed's management team is as well-rounded as it is experienced with a proven track record of success in drug delivery and commercialization. By combining a robust research background, industry expertise and sound business vision, we believe that our leadership is well prepared to guide the company into a promising future.

will lewisWill Lewis
President and Chief Executive Officer

Will Lewis joined Insmed in September 2012 as President and Chief Executive Officer and as a member of the Board of Directors. Mr. Lewis has more than 20 years of executive experience and a track record of success in the pharmaceutical and finance industries both in the US and internationally. Mr. Lewis is the former Co-Founder, President and Chief Financial Officer of Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR). During his tenure at Aegerion, Mr. Lewis played a pivotal role in re-orienting the company's strategy to focus on orphan disease indications enabling Aegerion to go public in one of the best performing IPOs of 2010. Prior to Aegerion, Mr. Lewis spent 10 years working in the U.S. and Europe in investment banking for JP Morgan, Robertson Stephens and Wells Fargo. During his time in banking, he was involved in a broad range of domestic and international capital raises and advisory work valued at more than $20 billion. Mr. Lewis serves as a member of the Supervisory Board of uniQure N.V. (Nasdaq: QURE). Mr. Lewis also serves as a member of the Board of BioNJ, as a member of the Board of Directors of Oberlin College, and as a member of the Visiting Committees of the Weatherhead School of Management of Case Western Reserve University and The Hawken School. Mr. Lewis holds a Bachelor of Arts degree cum laude from Oberlin College and a Master of Business Administration/Juris Doctor with Honors from Case Western Reserve University. Prior to attending graduate school he worked in the Foreign Service for the US Government.


andy drechslerAndrew Drechsler
Chief Financial Officer

Andy Drechsler joined Insmed as Chief Financial Officer in November 2012. He offers 15 years of financial and operational leadership experience in both public and private life sciences companies. Mr. Drechsler joins Insmed from VaxInnate Corporation, a privately held clinical-stage biotechnology company developing vaccines for infectious diseases, where he was Chief Financial Officer. During his five years with VaxInnate, he led multiple financing transactions totaling more than $55 million. Previously, he was Chief Financial Officer of publicly-traded Valera Pharmaceuticals where he helped raise $35 million through an initial public offering in 2006, completed a licensing and investment agreement with a partner for two products and worked with senior management to build a commercial team. Mr. Drechsler was part of the team that negotiated the sale of the company to Indevus Pharmaceuticals in 2007 in a transaction valued at $150 million. His public company and financial reporting duties have also included serving as controller for a variety of companies, including Abbott Laboratories’ Point of Care Division, which was publicly-traded as i-Stat Corporation prior to being acquired by Abbott, and Biomatrix, Inc., which was publicly-traded prior to being acquired by Genzyme. Mr. Drechsler graduated Magna Cum Laude from Villanova University with a BS in Accounting and received his certified public accountant license in New Jersey. 


christine pellizzariChristine Pellizzari
General Counsel & Corporate Secretary

Christine Pellizzari joined Insmed in July 2013. She brings nearly 20 years of senior-level leadership experience in the global biotechnology and pharmaceutical industry.  Most recently, Ms. Pellizzari served as Executive Vice President, General Counsel and Secretary of Aegerion Pharmaceuticals, Inc., a publicly traded company developing therapies for rare diseases.  Among her accomplishments and responsibilities at Aegerion, Ms. Pellizzari oversaw all the legal aspects of that company’s successful IPO and secondary public offering and served as a member of the Executive Management Committee.  Prior to joining Aegerion, Ms. Pellizzari served as Senior Vice President, General Counsel and Secretary of Dendrite International, Inc., a publicly traded company that provided sales effectiveness, promotional and compliance solutions to the global pharmaceutical industry.  She was a member of the company's Executive Operations Management Committee and helped lead many critical initiatives during her 9 year tenure, including the sale of the company to Cegedim S.A. in May, 2007.  Ms. Pellizzari joined Dendrite from the law firm of Wilentz, Goldman & Spitzer where she specialized in health care transactions and related regulatory matters. Before joining Wilentz, Ms. Pellizzari served as law clerk to the Honorable Reginald Stanton, Assignment Judge for the Superior Court of New Jersey. Ms. Pellizzari received her BA, cum laude, from the University of Massachusetts, Amherst and her JD from the University of Colorado, Boulder.


walter perkinsWalter Perkins, PhD
Chief Technology Officer

Walter Perkins joined Insmed in December 2010 in connection with the business combination between Insmed and Transave. Prior to this, Dr. Perkins joined Transave in 2002 and served as Chief Technology Officer. Dr. Perkins has over 20 years experience utilizing lipid-based drug delivery systems and has authored over 66 scientific publications and patent applications. Prior to joining Transave, Dr. Perkins spent 15 years with The Liposome Company (later a part of Elan Drug Delivery). At The Liposome Company, Dr. Perkins was involved in the design of several lipid-based drug delivery systems, including an artificial lung surfactant formulation, and helped in the characterization, development and launch of the company's two commercial products Abelcet® and Myocet®. As a part of Elan's Drug Delivery Division, he played a lead role in the implementation of liposome technology in both inter-divisional projects and corporate partnerships. Dr. Perkins received his bachelor's and doctoral degrees in Biophysical Chemistry from the University of Virginia where he studied the physical and electrical properties of liposomal membranes.


Nicole SchaefferS. Nicole Schaeffer
Senior Vice President, Human Resources and Corporate Services

Ms. Schaeffer joined Insmed in October 2012. She brings more than 20 years of experience in Human Resources, organizational development, corporate operations and building life science organizations. Most recently Ms. Schaeffer served as Senior Vice President, Administration and Human Resources, for Amicus Therapeutics where she was responsible for the human resources, facilities and IT functions. While at Amicus, Ms. Schaeffer was responsible for the organizational growth and development of this high performing company from its earliest stages to its current position as a late-stage clinical company. During this time, she focused on developing a culture of excellence to support that growth. Prior to Amicus, she served as Senior Director, Human Resources, for three portfolio companies of Flagship Ventures, a venture capital firm, and in that capacity she managed human resources for three life sciences companies. She has also held HR leadership positions with Oak Industries and EMC Corporation. Ms. Schaeffer received her BA from the University of Rochester and her MBA from Boston University.


peggy berryPeggy Berry
Vice President, Regulatory Affairs

Peggy Berry joined Insmed in February 2014 as Vice President of Regulatory Affairs. Ms. Berry is responsible for the development and implementation of global regulatory strategies and the management and oversight of the Regulatory Affairs department. Prior to joining Insmed, she held a variety of senior level positions in Amarin, Dyax, AstraZeneca, and Dey Pharma. She has also held roles at two clinical contract research organizations within Regulatory Affairs (ILEX Oncology and Cato Research Ltd.) and has worked in review divisions at the FDA. In addition, Ms. Berry consults for a number of companies in the regulatory and quality area and is active in the Regulatory Affairs Professionals Society. She is the editor of the 2010 book “Choosing the Right Regulatory Career” (RAPS, MD) and author of the 2011 book “Communication & Negotiation” (RAPS, MD). Ms. Berry has an MBA from The University of Phoenix and a B.S. in Biology from Charter Oak State College in Connecticut.


peter clarkePeter Clarke, PhD
Vice President, Technical Operations

Peter Clarke joined Insmed as Vice President of Manufacturing in April 2013. He offers more than 28 years in the biopharmaceutical industry in positions of increasing responsibility in both Europe and the US. He has worked for biotech start-ups bringing novel products to market as well as with multi-national companies such as Bayer being responsible for the manufacture and supply of established medicinal products. Dr. Clarke has led international teams that have developed manufacturing processes and their associated analytical methods for several classes of biopharmaceuticals. He has been the technical lead in facility design, commissioning, validation and start-up and has been responsible for the technical content of submissions to the FDA, EMA and other regulatory agencies. Prior to joining Insmed, Dr. Clarke was Group VP and Chief Technology Officer of Savient Pharmaceuticals, where he was responsible for manufacturing and supply chain management of Krystexxa and Oxandrin. Previously, he was VP Production and Technical Processes for Introgen Therapeutics where he led the manufacturing team for Advexin and liposome encapsulated DNA vectors. Dr. Clarke earned his PhD in Microbial Physiology from London University.


Gina EagleGina Eagle, MB, BS, FRACP
Vice President, Clinical Research

Dr. Eagle joined Insmed in April 2014 and was promoted to Vice President, Clinical Research in August. Dr. Eagle is a specialist pediatrician having trained in Australia. As a consultant pediatrician she had a general hospital patient intake and in addition specialty clinics in neurodevelopmental disorders. From neonatal to adolescent medicine, Dr. Eagle has treated a broad range of conditions in respiratory, cardiology, gastroenterology, endocrinology and neurology. Dr. Eagle also worked as a retrieval doctor, retrieving by helicopter or air ambulance newborns and children, from rural areas to major urban hospitals that required intensive or critical care. Dr. Eagle’s pharmaceutical industry career started with pharmacovigilence at J&J Australia. After relocating to the USA she joined Novartis, working in Neuroscience Medical Affairs on Alzheimer’s and Parkinson’s disease. Dr. Eagle’s interest in commercial and marketing led her to a job as a medical director at Cline Davis & Mann, a medical advertising company, where she worked on market research, product positioning and promotional materials in areas such as ADHD, schizophrenia, asthma, contraception and hemophilia. She then moved to biopharmaceuticals and worked at The Medicine’s Company, Mannkind Corporation, and more recently Aptalis Pharma, US. Dr. Eagle worked across all phases of clinical development in various therapeutic areas, from anti-infectives to diabetes to gastrointestinal disease. Dr. Eagle graduated from the Medical School at the University of New South Wales in Sydney Australia and has been admitted as Fellow of the Royal Australasian College of Physicians


john gollJohn Goll
Vice President, Corporate Controller

John Goll joined Insmed as Vice President, Corporate Controller in March 2014. He brings over 20 years of senior-level financial and accounting experience in the global pharmaceutical industry. Mr. Goll joins Insmed from Warner Chilcott plc, a publicaly traded global specialty pharmaceuticals company (acquired by Actavis plc in October 2013) focused on the women’s healthcare, gastroenterology, urology and dermatology segments of the branded pharmaceuticals market, where he was VP, Controller. During his over eight years with Warner Chilcott, his responsibilities included global inrernal and external financial reporting and all SEC filings. He played an integral role in building a global finance team and his work included many important initiatives, including the company’s successful $1.1 billion IPO in 2006 and multiple follow-on secondary offerings and financings, as well as, the transformative acquisition of P&G’s global pharmaceuticals business in 2009. Previously, he was Director, Financial Planning & Analysis at Alpharma Inc., a publicly-traded human and animal pharmaceuticals company and was a Senior Accountant at RD Hunter & Company LLP, CPAs. He graduated from The College of New Jersey with a BS in Accounting and holds an MBA in Finance from Fairleigh Dickinson University. Mr. Goll is a licensed certified public accountant in New Jersey.


wes kaupinenWes Kaupinen
Vice President, Corporate Development and Commercialization

Wes Kaupinen joined Insmed in August 2013 as Vice President of Corporate Development and Commercialization, bringing extensive experience in corporate strategy, business development, finance, and sales management and operations. Prior to joining Insmed, Mr. Kaupinen was a senior investment professional with Quaker Partners, a healthcare venture capital and growth equity firm, where he led and was involved in a number of public and private investments in emerging growth companies in the biotech, specialty pharma, and medical device sectors. While with Quaker, Mr. Kaupinen served as a member of the Board of Directors of TELA Bio and Intact Vascular, and was closely involved in Quaker’s investments in NovaSom, Horizon Pharma, and Achillion Pharmaceuticals. Mr. Kaupinen previously held various sales and marketing roles at Synthes and J&J Cordis Cardiology, including serving as part of the senior sales leadership team for Synthes U.S. Trauma Division. Prior to joining Synthes, Mr. Kaupinen worked in the Healthcare Group at Apax Partners, a global private equity firm, where he worked closely on Apax’s investments in Skinmedica (sold to Allergan) and ESP Pharma (sold to Protein Design Labs). Mr. Kaupinen began his career in the Life Sciences Group at Robertson Stephens where he focused on M&A and corporate finance.  Mr. Kaupinen has an MBA from The Wharton School of The University of Pennsylvania where he was the recipient of the William L. Kissick M.D. Scholarship Award, and a B.A. in Economics from The University of Virginia.


Kevin J. McDermottKevin J. McDermott
Vice President, Global Market Access

Kevin McDermott joined Insmed in March 2014 as Senior Director, Global Market Access and was promoted to Vice President, Global Market Access in August 2014. Mr. McDermott brings more than 20 years of commercial experience in the biopharmaceutical industry. Most recently, Mr. McDermott served as Vice President, Managed Markets for Aptalis Pharma where he and his team successfully built up the market appreciation and use of Aptalis’ Cystic Fibrosis GI care management offerings. Prior to joining Aptalis Mr. McDermott served as Vice President, Managed Markets at Daiichi Sankyo. While at Daiichi Sankyo he built the Value Selling, Pull Through, Contracting, Trade & Institutional, Customer Value Marketing and Value Pricing & Access functions into a top performing account management team. Mr. McDermott also led an entire managed care department at Aventis (now Sanofi) Pasteur. For nearly four years, leading the company’s efforts to improve the reimbursement and utilization of pediatric, adolescent and adult vaccines. Mr. McDermott began his career as a Sales Representative at Parke-Davis where he moved up through the traditional ranks of sales and discovered the importance of managed care in 1990 where he managed the Central U.S.  Mr. McDermott received a Bachelor of Arts degree cum laude from Hillsdale College.


Mark QuigleyMark A. Quigley, PhD
Vice President, Quality Assurance

Mark Quigley joined Insmed in September 2013 as Vice President Quality Assurance. Dr. Quigley brings over 30 years of pharmaceutical industry experience spanning a number of operational areas including clinical research, medical affairs, pharmacovigilance, regulatory affairs and quality assurance. Prior to joining Insmed, Dr. Quigley was the Executive Vice President of Quality and Compliance at Icon PLC, a contract research organization (CRO), where he was responsible for quality assurance and training for all divisions of the company globally. Prior to Icon PLC, Dr. Quigley held the position of Global Vice President of Quality & Compliance for Sanofi. Dr. Quigley began his career as a hospital pharmacist in a large teaching hospital, where he lead the intravenous admixture program and performed pharmacoeconomic evaluations along with the traditional activities. He left to join Marion Laboratories in 1980 as a Senior Scientist in clinical research. From there, Dr. Quigley progressed to head the pharmacovigilance organization, and following merger activity, the Senior Director of U.S. Drug Regulatory Affairs for Marion Merrell Dow. He became Vice President of Global Regulatory Compliance and Product Surveillance with Hoechst Marion Roussel and then Global Head - Vice President of Global Quality Assurance/Compliance and Regulatory Chemistry Manufacturing and Controls for Aventis. During his career he was involved with numerous products developed and commercialized in countries worldwide and was directly involved with regulatory agencies. Dr. Quigley holds a Bachelor of Science degree in Pharmacy, a Master of Science in Pharmaceutical Science and a Ph.D. in Pharmaceutical Science with a minor in Quantitative Analysis, and is a certified fraud examiner (CFE). He also served as an adjunct assistant professor of Pharmacy at the University of Missouri where he was involved with graduate students and sat on Ph.D. research committees.


ARIKAYCE

(liposomal amikacin
for inhalation)

arikace nebulizer

A differentiated, once-a-day inhaled antibiotic engineered to deliver a proven and potent anti-infective directly to the site of serious lung infections to improve the efficacy, safety and convenience of treatment for patients.

Learn More